Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Authors :: Ravandi F
Ritchie EK
Sayar H
Lancet JE
Craig MD
Vey N
Strickland SA
Schiller GJ
Jabbour E
Pigneux A
Horst HA
Récher C
Klimek VM
Cortes JE
Carella AM
Egyed M
Krug U
Fox JA
Craig AR
Ward R
Smith JA
Acton G
Kantarjian HM
Stuart RK
Source :: Haematologica [Haematologica] 2018 Nov; Vol. 103 (11), pp. e514-e518. Date of Electronic Publication: 2018 May 24.
Publication Year :: 2018

Subjects :: Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols adverse effects
Cytarabine administration & dosage
Cytarabine adverse effects
Female
Humans
Male
Middle Aged
Naphthyridines administration & dosage
Naphthyridines adverse effects
Recurrence
Thiazoles administration & dosage
Thiazoles adverse effects
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute mortality

Full Text Access

Tools